Epcoritamab in B-cell malignancies: current status and prospects

References

• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 Mar 2;376(9):836–847. doi: 10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1055–1065.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell Lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023 Apr 20;41(12):2238–2247. doi: 10.1200/JCO.22.01725
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2022 Dec 15;387(24):2220–2231. doi: 10.1056/NEJMoa2206913
   PubMed Web of Science ®Google Scholar
• Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327–e339.
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495–505. doi: 10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259–2267.
   PubMed Web of Science ®Google Scholar
• Lee HC, Bumma N, Richter JR, et al. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. Clin Oncol. 2023;41(suppl 16):8006. doi: 10.1200/JCO.2023.41.16_suppl.8006
   Web of Science ®Google Scholar
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232–2244. doi: 10.1056/NEJMoa2204591
   PubMed Web of Science ®Google Scholar
• Riaz R, Khan A, Siddiqui T. Epcoritamab-bysp (epkinly) – a phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma. Rare Tumors. 2023 Jul 31;15:20363613231193566. eCollection 2023. doi: 10.1177/20363613231193566
   Web of Science ®Google Scholar
• van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J.2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. [ 2023 May 19 accessed May 31, 2023].
   Google Scholar
• Genmab announces European Commission approval of tepkinly (epcoritamab) for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). News Release. Genmab A/S. Sep 25, 2023 Accessed oct 23, 2023.
   Google Scholar
• Genmab and AbbVie announce positive topline results from phase 1/2 EPCORE™ NHL-1 trial evaluating epcoritamab (DuoBody® CD3xCD20) in patients with relapsed/refractory follicular lymphoma (FL). News Release. Genmab. Jun 28, 2023 Accessed Jun, 28 2023. Available from: https://ir.genmab.com/news-releases/news-release-details/genmab-and-abbvie-announce-positive-topline-results-phase-12
   Google Scholar
• Kater AP, Eradat H, Niemann CU, et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort. Presented at: 2023 International Workshop on CLL; 2023 Oct 6–9; Boston. Abstract 1546171.
   Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306):1157–1169. doi: 10.1016/S0140-6736(21)00889-8
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3067. doi: 10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Karimi Y, Ghesquieres H, Jurczak W, et al. Longer follow-up reaffirms subcutaneous epcoritamab induces deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial. Clin Lymphoma Myeloma Leukemia. 2023 Sep;23(Supplement 1):S147. SOHO 2023; Abstract ABCL-500. doi: 10.1016/S2152-2650(23)00355-5
   Google Scholar
• Phillips T, Lugtenburg P, Kalsekar A, et al. Improvements in lymphoma symptoms and health-related quality of life in patients with relapsed or refractory large B-Cell lymphoma treated with subcutaneous epcoritamab (EPCORE NHL-1). Blood. 2022;140(Supplement 1):8022–8023. doi: 10.1182/blood-2022-159544
   Google Scholar
• Clausen MR, Offner F, Belada D, et al. Subcutaneous epcoritamab + R-CHOP for the first-line treatment of patients with high-risk DLBCL: Phase ½ update. Hemasphere. 2022 Jun;6(Suppl):1100–1101.
   Google Scholar
• Sehn LH, Chamuleau M, Lenz G, et al. Phase 3 trial of subcutaneous epcoritamab + R-chop versus R-chop in patients (PTS) with newly diagnosed diffuse large b-cell lymphoma (DLBCL): epcore DLBCL-2. Hem Oncol. 2023;41(Suppl):849–850. doi: 10.1002/hon.3166_OT28
   Google Scholar
• Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638–1651. doi: 10.1002/ajh.26737
   PubMed Web of Science ®Google Scholar
• Linton K, Jurczak W, Lugtenburg P, et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the EPCORE NHL-1 follicular lymphoma dose-expansion cohort. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; Dec 9-12, 2023; San Diego, CA: Abstract 1655
   Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934–947. doi: 10.1056/NEJMoa1805104
   PubMed Web of Science ®Google Scholar
• Sureda A, Falchi L, Leppa S, et al. Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status. Hemasphere. 2023 Aug;7(Suppl):e5547136.
   Google Scholar
• Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023 Mar 21;329(11):918–932. doi: 10.1001/jama.2023.1946
   PubMed Web of Science ®Google Scholar
• Iovino L, Shadman M. CAR T-cell therapy for CLL: a new addition to our treatment toolbox? Clin Adv Hematol Oncol. 2023;21(3):134–141.
   PubMed Web of Science ®Google Scholar
• Kater AP, Ye JC, Sandoval-Sus J, et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022;140(suppl 1):850–851. doi: 10.1182/blood-2022-15829
   Google Scholar
• Mhibik M, Gaglione EM, Eik D, et al. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv. 2023;7(15):4089–4101. doi: 10.1182/bloodadvances.2022009517
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Jun M, Munoz J, et al. Comparison of the efficacy of epcoritamab versus chimeric antigen receptor therapies, polatuzumab-based regimens, and tafasitamab-based regimens. Hemasphere. 2023 Aug;7(Suppl):e9299527.
   Google Scholar
• Major A, Kamdar M. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. Hematology Am Soc Hematol Educ Program 2023. 2023 Dec 8;2023(1):370–381.
   PubMedGoogle Scholar
• de Assis LH, Fassi DE, Hutchings M. Bispecific antibody therapies. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):216–222. doi: 10.1182/hematology.2023000508
   PubMedGoogle Scholar
• Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Rev Hematol. 2023 Jul;16(12):915–918.
   PubMed Web of Science ®Google Scholar